This past month on HCPLive, several important topics were covered as part of our dermatology content from March.
The list includes new trial data on psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and prurigo nodularis (PN) treatment options.
The following list is a summary of these major breakthroughs covered in March in the dermatology space, with more news and updated content on these topics available on the HCPLive main news page.
1. Positive Phase 3 Trial Results for Tapinarof Cream on Atopic Dermatitis
In this HCPLive article, phase 3 data from the ADORING 2 trial indicated that about of half of AD patients treated with tapinarof, 1% showed improvement on the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM).
The investigators noted that tapinarof may be potential two-in-one first-line topical treatment for both atopic dermatitis and plaque psoriasis, as the new trial found the cream to be both safe and tolerable for all age groups down to 2 years.
The study results were announced by biopharmaceutical company Dermavant Sciences.
2. Positive Trial Results for Hand, Foot Eczema Patients Treated with Dupilumab
This late-breaking data was shown at the American Academy of Dermatology (AAD) 2023 conference, showing that about 40% of uncontrolled moderate-to-severe hand and foot AD patients achieved clear or almost clear skin compared to 17% with placebo.
The researchers saw improvements as early as 1 week, noting that there were substantial improvements in measures of sleep, skin pain, as well as hand eczema-related life quality. They noted that the drug was the first biologic evaluated for this particular patient population.
The data was presented by Eric Simpson, MD, the studys principal trial investigator.
3. Nemolizumab Treatment Led to Improved Skin Lesions, Itch for Prurigo Nodularis Patients
Phase 3 data from the OLYMPIA 2 trial, presented at AAD, showed that nemolizumab monotherapy improved skin lesions, itch, and sleep disturbances in adults with moderate-to-severe prurigo nodularis (PN).
The investigators reported that nemolizumab, a first-in-class, interleukin-31 receptor alpha antagonist, met all of the studys primary and key secondary endpoints.
The late-breaking results were presented by Shawn Kwatra, MD, from Johns Hopkins University School of Medicine.
4. Once Daily Roflumilast Improved Symptoms of Atopic Dermatitis in Phase 3 Trials
This late-breaking data, presented at AAD, showed that roflumilast 0.15% once-daily improved AD across multiple efficacy endpoints and produced favorable safety and tolerability in patients.
The results showed that adverse events (AEs) were reported in less than 3.5% of patients, and application site pain incidence was low. The data resulted from the INTEGUMENT-1 and INTEGUMENT-2 studies.
The results were presented by Lawrence Eichenfield, MD, from Rady Children's Hospital.
5. Phase 3 Trial Data on Bimekizumab for Patients with Hidradenitis Suppurativa
This data, also presented at AAD, indicated that a greater percentage of HS patients achieved HiSCR50 for those treated with bimekizumab compared to placebo at week 16 of the study.
The results came from the BE HEARD I and II trials investigating the selective inhibition of IL-17F and IL-17A by bimekizumb, a monoclonal IgG1 antibody.
The research was presented at the conference by lead investigator Alexa B. Kimball, MD, from Beth Israel Deaconess Medical Center.
6. Oral Roflumilast Effective, Safe in Treating Plaque Psoriasis Over 24 Weeks
In this study, oral roflumilast treatment was found to lead to significant Psoriasis Area and Severity Index (PASI) score, with 34.8% of their treatment group reached PASI75 compared to 0.0% in given placebo by week 12.
The late-breaking data on oral roflumilast, a targeted phosphodiesterase (PDE)-4 inhibitor, was presented at AAD 2023. The research team also stated that roflumilast may become a cheap alternative treatment to other psoriasis drugs with more research.
The findings were presented by Alexander Egeberg, MD, PhD, from the University of Copenhagen and Bispebjerg Hospital.
7. Oral TYK2 Inhibitor Led to Significant Skin Clearance Improvement in Psoriasis
These results showed that treatment with TAK-279 (formerly NDI-034858), an oral tyrosine kinase 2 (TYK2) inhibitor, led to significant skin clearance improvement for moderate-to-severe psoriasis patients compared to placebo, especially at a once-daily, 5 mg dose.
The phase 2b clinical trial data was shown at AAD, and the investigators demonstrated that at the highest dose of TAK-279, 33% of study participants reached complete skin clearance by week 12.
The data was presented at the conference by April W. Armstrong, MD, MPH, from USCs Keck School of Medicine.
Read this article:
Dermatology Month in Review: Highlights from March 2023 - MD Magazine
- Advancing Hidradenitis Suppurativa Care - Early Diagnosis, Biologic Therapies, and Multidisciplinary Approaches: Part 3 - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Top 5 Articles of the Month: March - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Talking to Patients on Sunscreen Application and the Effects of Visible Light - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Clinical Experience and Diagnosis of GPP - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Fixed-Dose Acne Treatment Gel is Safe and Effective for Hispanic Patients, According to Post-Hoc Analysis - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- CBD and CBG Ointment Improved Skin in Patients with Atopic Dermatitis - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma - Dermatology Times - March 30th, 2025 [March 30th, 2025]
- Hims & Hers shutters Apostrophe in favor of its own tele-dermatology offerings - Fierce healthcare - March 15th, 2025 [March 15th, 2025]
- Closing Out AAD With Dermatology Times Editor in Chief - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Improving Patient Care in Dermatology Through Data, Innovation, Advocacy: AAD 2025 Recap - AJMC.com Managed Markets Network - March 15th, 2025 [March 15th, 2025]
- Inflammatory Arthropathy Risk Increased in Patients With Hidradenitis Suppurativa - Dermatology Advisor - March 15th, 2025 [March 15th, 2025]
- Expert Perspectives: Dermatology's Top Story to Watch in 2025 - MD Magazine - March 15th, 2025 [March 15th, 2025]
- Whats New in Dermatology for Pigmentary Disorders, with Andrew Alexis, MD, MPH - MD Magazine - March 15th, 2025 [March 15th, 2025]
- Home Phototherapy Proves Effective and Preferred in LITE Study for Psoriasis Treatment - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Reviving the Classics: The Role of Older Medications in Modern Dermatology - AJMC.com Managed Markets Network - March 15th, 2025 [March 15th, 2025]
- Dermatology Therapeutics: Updates for Primary Care from AAD 2025 - Patient Care Online - March 15th, 2025 [March 15th, 2025]
- Advances in Dermatology Therapeutics: Key Insights from AAD 2025 - Patient Care Online - March 15th, 2025 [March 15th, 2025]
- The Impact of JAK Selectivity in Atopic Dermatitis Treatment - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Social Drivers of Health Success Stories in Dermatology | AAD 2025 - Managed Healthcare Executive - March 15th, 2025 [March 15th, 2025]
- Improving Acne Treatment Through Antibiotic Stewardship and Gut-Skin Health - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Advancing Recognition and Treatment of Allergic Contact Dermatitis - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- Lebrikizumab Shows 3-Year Sustained Efficacy in AD - Dermatology Times - March 15th, 2025 [March 15th, 2025]
- AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum -... - March 5th, 2025 [March 5th, 2025]
- What to Look Forward to at the American Academy of Dermatology Annual Meeting 2025 - MD Magazine - March 5th, 2025 [March 5th, 2025]
- Recognizing the Achievements of Women in Dermatology - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- The Solar Spectrum and Impact on Skin Health - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- The Undetectable Era: How Patients Are Shifting Towards More Natural-Looking Results at the Clinic - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Researchers overseas: Radiology has become indispensable to dermatology - Radiology Business - March 5th, 2025 [March 5th, 2025]
- Defining Alopecia Areata Severity and Navigating Treatment Options - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Acne and TikTok: What Do Dermatologists Need to Know? - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Celebrating Womens History Month with Mindy Haws, MD, and the LIMITLESS Initiative - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- A Case-Based Approach to Topical and Nonsteroidal AD Management - Dermatology Times - March 5th, 2025 [March 5th, 2025]
- Dermatology Partners Opens State-of-the-Art Dermatopathology Laboratory - citybiz - February 25th, 2025 [February 25th, 2025]
- Ethical Considerations and Guidance of Cosmeceuticals in Pediatric Care - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- AI in Dermatology: Emerging Insights and Diverging Perspectives - MD Magazine - February 25th, 2025 [February 25th, 2025]
- Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical... - February 25th, 2025 [February 25th, 2025]
- Aesthetic Treatments: More Than Just Enhancements, A Path to Empowerment - Dermatology Times - February 25th, 2025 [February 25th, 2025]
- Samitivej to advance dermatology and aesthetic medicine in new partnership - Healthcare Asia - February 25th, 2025 [February 25th, 2025]
- Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with... - February 25th, 2025 [February 25th, 2025]
- U.S. Dermatology Partners Ranked the No. 1 Dermatology Group in the Nation by Castle Connolly - PR Newswire - February 3rd, 2025 [February 3rd, 2025]
- Alopecia Areata Risk May be Associated With Serum Vitamin D and Zinc Levels - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Age at Melanoma Diagnosis Varies by Sex, Anatomic Site, and Tumor Thickness - Dermatology Advisor - February 3rd, 2025 [February 3rd, 2025]
- Dermatology Medications and Solutions Market Poised to Growth USD 51.7 Billion by 2032 with Thriving CAGR of - EIN News - January 23rd, 2025 [January 23rd, 2025]
- Optimizing Care for Patients with Urticaria - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Advancing Care With Laser and Light-Based Technology in Dermatology - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Online Dermatology Consultation Market: CAGR of 15.4% Expected by 2025 Due to Increasing Skin Health Awareness - openPR - January 23rd, 2025 [January 23rd, 2025]
- VP-315 Demonstrates Positive Topline Results in Basal Cell Carcinoma - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- AI and the Future of Cosmetic Dermatology: Experts Weigh in - Medscape - January 23rd, 2025 [January 23rd, 2025]
- When and How to Employ the Buy and Bill Model - Dermatology Times - January 23rd, 2025 [January 23rd, 2025]
- Innovating Scalp Care: How Research and Education Drive Solutions - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Rare Overlap of 2 Autoinflammatory Keratinization Diseases Observed in Single Lesion - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Expanding Laser Benefits for Diverse Patient Populations - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times - January 15th, 2025 [January 15th, 2025]
- Kwon Min-ah, a former member of the group AOA, became the head of the dermatology consultation offic.. - - January 15th, 2025 [January 15th, 2025]
- Top 5 Dermatology Articles of 2024 - Managed Healthcare Executive - January 1st, 2025 [January 1st, 2025]
- DEI programs, sun safety: Read this years top practice management articles in dermatology - Healio - January 1st, 2025 [January 1st, 2025]
- Cutaneous Connection 2024: Top Dermatology Podcast Episodes and Insights of the Year - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Top Insights and Highlights from Dermatology Times' Interview Intersection: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Reviewing Major Dermatologic Studies of the Year: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Peak Dermatology in Visalia hopes to provide more skin services and treatment to the area - KFSN-TV - December 23rd, 2024 [December 23rd, 2024]
- Krystal Tawney of Pinnacle Dermatology celebrates 10 years of business in the Greenbrier Valley - Real WV - December 23rd, 2024 [December 23rd, 2024]
- Supporting Pediatric Patients With AD and Their Caregivers - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Photodynamic Therapy is an Effective, Long-Term Treatment for Actinic Keratosis - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Advanced Dermatology to pay $15G fine after doctor refused to perform procedure on HIV-infected patient - Newsday - December 9th, 2024 [December 9th, 2024]
- Efficacy of Combining Postbiotic Formulation with Microneedling for Acne - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Opioid-Prescribing Trends in Dermatology From 2014 to 2020 in the United States - Cureus - November 28th, 2024 [November 28th, 2024]
- Amid challenges, the Baton Rouge dermatology industry is evolving - Greater Baton Rouge Business Report - November 28th, 2024 [November 28th, 2024]
- Polynucleotide Therapy Shows Promise in Scar and Burn Management - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Revolutionizing Dermatology: How Emerging Technologies are Shaping the Future of Skin Care - Spherical Insights - November 28th, 2024 [November 28th, 2024]
- Dermatology OTC Medications Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033 - openPR - November 28th, 2024 [November 28th, 2024]
- Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases: Part 2 - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Patient Education and Novel Topical Therapies for AD - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- TikTok dermfluencers have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week -... - November 20th, 2024 [November 20th, 2024]